◀ Back to SMAD2

MSTN — SMAD2

Text-mined interactions from Literome

Allen et al., Am J Physiol Cell Physiol 2007 : Here we examined the role of FoxO1 and SMAD transcription factors in regulating myostatin gene expression and myoblast differentiation in C ( 2 ) C ( 12 ) myotubes in vitro
Costelli et al., Eur J Clin Invest 2008 (Cachexia...) : In day 4 tumour hosts muscle myostatin levels were comparable to controls, yet follistatin was reduced, and SMAD DNA binding activity was enhanced
Ciarmela et al., Endocrinology 2009 : Functional assays showed that myostatin induced phosphorylation of Smad-2 and reduced proliferation of PHM1 number in a time and dose dependent manner
Yuzawa et al., Bone 2009 : Knockdown of Arkadia increased the Myostatin induced phosphorylation of Smad2/3 in C2C12 cells
Watt et al., Muscle Nerve 2010 (Hypertrophy) : SB431542 treatment reduced myostatin induced C-terminal Smad2 phosphorylation and resulted in the formation of enlarged myotubes
Miyake et al., Biochem Biophys Res Commun 2010 : Overexpression of TIEG1 prevented the transcriptional activation of Smad by myostatin and TGF-beta in both proliferating or differentiating C2C12 cells, but the expression of Smad2 and Smad7 mRNAs was not affected
Bo Li et al., J Cell Sci 2012 (Fibrosis...) : Here, we demonstrate that myostatin also regulates the proliferation of dystrophic muscle fibroblasts, and increases resistance of fibroblasts to apoptosis through Smad and MAPK signaling
Watts et al., Am J Physiol Cell Physiol 2013 : Free myostatin induces the phosphorylation of the Smad family of transcription factors, which, in turn, regulates gene expression, via the canonical TGF-ß signaling pathway